Showing results (571-580 of 1,074) with videos related to

Sort By:
Pageof 108
Therapeutic Advances in Neurological Disorders|September 4, 2025
Racial and ethnic disparities in ALS: a longitudinal electronic health records studyTiffany Kuo, Timothy Reynolds, Linda Chen, et al.
Therapeutic Advances in Neurological Disorders|August 11, 2021
Corrigendum to "Diagnosing small fiber neuropathy in clinical practice: a deep phenotyping study"
Therapeutic Advances in Neurological Disorders|May 26, 2021
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trialAlasdair J Coles, Douglas L Arnold, Ann D Bass, et al.
Therapeutic Advances in Neurological Disorders|May 26, 2021
PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathyNora Möhn, Mike P Wattjes, Ortwin Adams, et al.
Therapeutic Advances in Neurological Disorders|May 3, 2014
Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registryGeorgios Tsivgoulis, Christos Krogias, Kara A Sands, et al.
Therapeutic Advances in Neurological Disorders|May 3, 2014
Para-dichlorobenzene toxicity - a review of potential neurotoxic manifestationsDivyanshu Dubey, Vibhash D Sharma, Steven E Pass, et al.
Therapeutic Advances in Neurological Disorders|November 2, 2016
Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosisLana Zhovtis Ryerson, Rivka Green, Gladyne Confident, et al.
Therapeutic Advances in Neurological Disorders|November 2, 2016
An update on the evidence base for peginterferon β1a in the treatment of relapsing-remitting multiple sclerosisPavan Bhargava, Scott D Newsome
Therapeutic Advances in Neurological Disorders|April 7, 2017
Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatmentGisa Ellrichmann, Ralf Gold, Ilya Ayzenberg, et al.
Therapeutic Advances in Neurological Disorders|March 28, 2017
Interactions among COX-2, GPIIIa and P2Y1 variants are associated with aspirin responsiveness and adverse events in patients with ischemic strokeXingyang Yi, Zhao Han, Qiang Zhou, et al.
Pageof 108